PD patients exhibit dual ENS pathology: α-synuclein aggregation within enteric neurons and progressive loss of cholinergic/nitrergic neurons. This disrupts gut motility causing constipation, SIBO, and dysbiosis blooms (H. pylori, Klebsiella). Enteric glial reactivity and S100B release complete a feedforward inflammatory loop. Clinical observations are robust; the primary weakness is circular logic regarding initiating event. Gut-directed therapies (prokinetics, H. pylori eradication, FMT) may break this cycle.
Curated pathway from expert analysis
flowchart TD
A["SNCA Alpha-Synuclein<br/>Presynaptic Protein"]
B["SNCA Misfolding<br/>Environmental Stress"]
C["SNCA Oligomers<br/>Toxic Protofibrils"]
D["Mitochondrial Pore<br/>Membrane Disruption"]
E["Lewy Body Formation<br/>Cytoplasmic Inclusions"]
F["Dopaminergic Neuron<br/>Dysfunction/Death"]
G["Nigrostriatal Degeneration<br/>Motor Symptoms"]
H["SNCA A53T/A30P/E46K<br/>Familial PD Mutations"]
A --> B
B --> C
C --> D
C --> E
D --> F
E --> F
F --> G
H -.->|"accelerates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style H fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8Median TPM across 13 brain regions for SNCA/GFAP/VIP/nNOS/CHAT from GTEx v10.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SNCA.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF H. pylori eradication therapy (10-day bismuth-based quadruple therapy: bismuth 300mg QID, tetracycline 500mg QID, metronidazole 500mg TID, omeprazole 20mg BID) is administered to treatment-naïve ea | ≥5-point reduction in MDS-UPDRS Part III score at 12 months; ≥20% reduction in serum zonulin; ≥30% improvement in constipation severity ( Wexner constipation sc | — no observation — | pending | 0.38 |
| IF enteric glial S100B signaling is pharmacologically blocked (using anti-S100B neutralizing antibody or S100B siRNA) in an α-synuclein overexpression mouse model (Thy1-SNCA transgenic), THEN measurab | ≥30% reduction in p-S129 α-synuclein in myenteric plexus; ≥25% improvement in gut transit time; ≥40% reduction in fecal inflammatory cytokines (IL-6, TNF-α) | — no observation — | pending | 0.45 |